Cellectar Introduces Phospholipid Ether-Drug Conjugate Platform
Cellectar Biosciences Inc. has launched its phospholipid ether-drug conjugate platform, a small-molecule cancer targeting and delivery technology for targeted delivery of chemotherapeutics.
The Madison, Wis.-based company says the platform has demonstrated highly selective cancer targeting both preclinically in more than 60 in vivo cancer models, and subsequently confirmed clinically in more than 10 cancer types.
Cellectar CEO Jim Caruso says the platform has the ability to link diverse oncologic payloads for targeted delivery to a broad range of cancer and cancer stem cell targets.
The platform’s payload, the firm says, has been validated using cytotoxic radioisotopes for cancer therapy, PET imaging isotopes for cancer imaging and fluorophores for image-guided surgery. — Michael Cipriano